The study investigates **Surabgene Lomparvovec**, a potential treatment for **neovascular age-related macular degeneration (nAMD)**, also known as "wet" AMD. This condition involves the growth of abnormal blood vessels in the retina, which is the light-sensitive part at the back of the eye. In this study, adults aged 50 and older who have been previously treated for nAMD will participate. Participants will be divided into three groups. Groups 1 and 2 will receive a single dose of the gene therapy Surabgene Lomparvovec as an injection between the retina and the back of the eye. Group 3 will receive a different treatment called **Ranibizumab**, injected into the jelly-like part inside the eye. The study will assess the treatment over a period of up to 5 years, requiring regular monthly visits to a hospital or clinic for medical assessments, blood tests, and questionnaires.
- Participation involves regular monthly visits over up to 5 years.
- Participants may receive different treatments based on group assignment.
- Medical assessments and questionnaires are part of the study.
How understandable was the trial content above?
Hard to understand
Easy to understand